Voltron Therapeutics develops precision-guided, self-assembling vaccines using the proprietary VaxCelerate™ technology to enhance cell-mediated immune responses against cancer and infectious diseases, including COVID-19. This approach aims to improve vaccine efficacy by targeting specific immune pathways, addressing the limitations of traditional vaccine designs.
Funding
$12.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional vaccines often fail to elicit strong cell-mediated immune responses, limiting their effectiveness against cancers and infectious diseases like COVID-19. These limitations stem from suboptimal targeting of immune pathways and inefficient antigen presentation to immune cells.
Solution
Voltron Therapeutics is developing precision-guided, self-assembling vaccines designed to enhance cell-mediated immunity. Their proprietary VaxCelerate™ technology enables the creation of vaccines that target specific immune pathways, improving the body's ability to fight cancer and infectious diseases. This approach aims to overcome the limitations of conventional vaccine designs by optimizing antigen presentation and stimulating a more robust and targeted immune response.
Target Audience
The primary target audience includes individuals at risk of infectious diseases and those affected by specific forms of cancer, as well as pharmaceutical companies and research institutions developing advanced vaccine technologies.
Features
- VaxCelerate™ self-assembling vaccine design for enhanced cell-mediated immune responses
- Precision-guided targeting of specific immune pathways
- Optimized antigen presentation to immune cells
- Potential application in vaccines for cancer and infectious diseases, including COVID-19